NCT06049017

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 2b Multicenter, Randomized, Placebo- Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 252 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

Conditions

• Colitis, Ulcerative

Interventions

Type	Name	Description
DRUG	JNJ-77242113	JNJ-77242113 tablet will be administered orally.
DRUG	Placebo	Placebo tablet will be administered orally.

Timeline

• Start date: 2023-10-09
• Primary completion: 2024-09-26
• Completion: 2026-01-05
• First posted: 2023-09-21
• Last updated: 2026-04-13

Locations

177 sites across 21 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Malaysia, Poland, Romania, South Korea, Spain, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study